Evidence map›Paper›PMID 40534232›Full record

ArticleThe Biochemical journal2025

Multiple transactivation domains of EZH2 bind to the TAZ2 domain of p300 and stimulate the acetyltransferase function of p300.

Dustin C Becht, Soumi Biswas, Chenxi Xu, Hongwen Xuan, Moustafa Khalil, Ling Cai, Catherine A Musselman, Xin Liu, El Bachir Affar, Xiaobing Shi and 2 more

Abstract read
In one paragraph

Article in The Biochemical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Dustin C BechtDepartment of Pharmacology, University of Colorado School of Medicine, Aurora CO 80045, U.S.A.
Soumi BiswasDepartment of Pharmacology, University of Colorado School of Medicine, Aurora CO 80045, U.S.A.
Chenxi XuDepartment of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham NC 27710, U.S.A.
Hongwen XuanDepartment of Epigenetics, Van Andel Institute, Grand Rapids, MI, U.S.A.
Moustafa KhalilMaisonneuve-Rosemont Hospital Research Center, Montréal, Québec H1T 2M4, Canada.
Ling CaiDepartment of Pathology, Duke University School of Medicine, Durham NC 27710, U.S.A.
Catherine A MusselmanDepartment of Biochemistry and Molecular Genetics, University of Colorado School of Medicine, Aurora CO 80045, U.S.A.
Xin LiuCecil H. and Ida Green Center for Reproductive Biology Sciences, The University of Texas Southwestern Medical Center, Dallas TX 75390, U.S.A.
El Bachir AffarMaisonneuve-Rosemont Hospital Research Center, Montréal, Québec H1T 2M4, Canada.
Xiaobing ShiDepartment of Epigenetics, Van Andel Institute, Grand Rapids, MI, U.S.A.
Gang Greg WangDepartment of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham NC 27710, U.S.A.
Tatiana G KutateladzeDepartment of Pharmacology, University of Colorado School of Medicine, Aurora CO 80045, U.S.A.ORCID 0000-0001-7375-6990

Funding

Women's Cancer Research ProgramP30CA014236 · NCI · DUKE UNIVERSITY · PI JOHN N. NORTON · 1985 to 2026
$174.8M
Molecular mechanisms of histone signaling in a chromatin relevant contextR35GM128705 · NIGMS · UNIVERSITY OF IOWA · PI Catherine Anne Musselman · 2018 to 2026
$3.8M
Dissecting and targeting canonical and non-canonical oncogenic functions of EZH2 in canerR01CA268519 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Jian Jin, G Greg Wang · 2022 to 2026
$3.2M
Molecular Basis of Gene Regulation by Polycomb Repressive Complex 2R35GM136308 · NIGMS · UT SOUTHWESTERN MEDICAL CENTER · PI LIU, XIN · 2020 to 2024
$2.9M
The Role of YY1 in Castration-Resistant Prostate CancerR01CA262903 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI CAI, LING · 2021 to 2025
$2.1M
Targeting acetylated histone H4 by MLL4R01AG067664 · NIA · UNIVERSITY OF COLORADO DENVER · PI KUTATELADZE, TATIANA G · 2021 to 2025
$2.1M
Molecular analysis of ASH1LR01CA252707 · NCI · UNIVERSITY OF COLORADO DENVER · PI TATIANA G KUTATELADZE · 2020 to 2026
$1.9M
High Throughput Screen for Inhibitors of the YEATS2 Histone Acylation ReaderR01CA268440 · NCI · VAN ANDEL RESEARCH INSTITUTE · PI SHI, XIAOBING · 2022 to 2025
$1.7M
Targeting acetylated histone H4 by MLL4R56AG067664 · NIA · UNIVERSITY OF COLORADO DENVER · PI KUTATELADZE, TATIANA G · 2020 to 2020
$512k
Understanding Molecular Crosstalk Between EZHIP and PRC2 in PFA EpendymomaR21NS137323 · NINDS · UT SOUTHWESTERN MEDICAL CENTER · PI LIU, XIN · 2024 to 2025
$445k
NCI NIH HHS P30 CA014236NCI NIH HHS R01 CA252707NCI NIH HHS R01 CA262903NCI NIH HHS R01 CA268440NCI NIH HHS R01 CA268519NIA NIH HHS R01 AG067664NIA NIH HHS R56 AG067664NIGMS NIH HHS R35 GM128705NIGMS NIH HHS R35 GM136308NIH HHS CA252707NINDS NIH HHS R21 NS137323
6 · The paper itself

Abstract

The H3K27me-specific methyltransferase enhancer of zeste homologue 2 (EZH2) is the catalytic subunit of the repressive complex Polycomb repressive complex 2. EZH2 is typically implicated in transcriptional silencing, but it can also activate gene expression. Here, we show that EZH2 contains three adjacent transactivation domains (EZH2TAD) that are recognized by the TAZ2 domain of the transcriptional coactivator and acetyltransferase p300 (p300TAZ2). Binding interfaces identified by chemical shift perturbations in NMR experiments, measurements of binding affinities, and analysis of the complex formation by mass photometry demonstrate that each EZH2TAD can be concomitantly bound by a separate p300TAZ2. Interaction of EZH2TADs with p300TAZ2 stimulates H3K18- and H3K27-specific acetyltransferase activity of p300. We show that in 22Rv1 prostate cancer cells, EZH2 occupies a large set of gene loci lacking H3K27me3, and these non-canonical genomic sites are instead co-occupied by p300, RNA Polymerase II and BRD4 and are rich in histone marks associated with transcriptional activation. Our findings shed light on the potential basis for such a high degree of genetic co-localization through the direct association of p300TAZ2 with EZH2TADs.

Indexed as

E1A-Associated p300 ProteinEnhancer of Zeste Homolog 2 Proteinp300-CBP Transcription FactorsTranscriptional ActivationBromodomain Containing ProteinsCell Cycle ProteinsCell Line, TumorHistonesHumansMaleProtein BindingProtein DomainsTranscription FactorsBRD4 protein, humanBromodomain Containing ProteinsCell Cycle ProteinsE1A-Associated p300 ProteinEnhancer of Zeste Homolog 2 ProteinEP300 protein, humanEZH2 protein, humanHistonesp300-CBP Transcription FactorsTranscription FactorschromatinEZH2p300TAZ2transactivation domain

Identifiers

PMID40534232
PMCPMC12312386

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.